AstraZeneca Kills Volrustomig Lung Trial, Discloses No Data

AstraZeneca killed a first-line lung cancer Phase 3 this week and released no efficacy data. None.

Meanwhile LEO Pharma paid up to four hundred and thirty-five million dollars for a rare disease pill already sitting at the FDA, and a new study says gray-market retatrutide is nowhere near trial numbers. Let's take the week apart.

Welcome to The Pharma Closeout Week in Review for Sunday, August 23rd. I'm Alex Mercer.

And I'm Maya Patel. One failure, one purchase, one unregulated experiment — and they rhyme more than you'd expect.

The story of the week is eVOLVE-Lung02, and the headline is what's missing from it. AstraZeneca discontinued the Phase 3 of volrustomig — their PD-1 by CTLA-4 bispecific — plus chemotherapy, in first-line metastatic non-small cell lung cancer with PD-L1 below fifty percent, running against pembrolizumab plus chemo. A planned interim review found the study unlikely to hit its co-primary endpoints. The independent monitoring committee recommended ending it.

And not one efficacy number came out with it.

Not one. Here's why that indication mattered so much. PD-L1-low first line is the largest untaken block left in lung cancer, and pembro plus chemo has held it for years — nobody has moved that wall. Volrustomig was the flagship, the asset AstraZeneca was building its next generation of checkpoint blockade around. This was the indication that justified the whole investment. Kill it and every remaining program in that molecule becomes a smaller bet by arithmetic.

The design detail nobody's saying out loud is where they aimed the primary analysis. It was PD-L1 under one percent, nested inside enrollment that ran up to fifty. So they powered the study on the slice with the least checkpoint biology in it — the slice where you'd argue the control arm is mostly chemotherapy doing the work. That's the setting they chose because it's the setting where you'd expect the delta to be widest.

And they still couldn't clear it.

On both co-primaries at once. That's the part I keep returning to. This isn't progression-free missing while survival matures — the committee looked at both and called it unlikely at interim. And we got no safety read either. A dual checkpoint stacked on a platinum doublet, and the discontinuation rate is the number I actually want.

Susan Galbraith, who runs oncology and hematology R&D there, called it a disappointment and said they'd carry the lessons forward. The molecule continues in three remaining Phase 3s — mesothelioma, cervical, and head and neck squamous cell.

But not in the indication that paid for it. Which is where I'd push back on how you've been framing this all week. You've read it as an indictment of next-generation checkpoint blockade. There's no data supporting that read — because there's no data at all. What we actually know is that one bispecific, in the hardest first-line population in oncology, against the strongest control arm in oncology, failed to clear a co-primary bar at interim. That's a verdict on a trial design at least as much as on a mechanism.

I'll take the correction on the mechanism — you're right that I can't indict biology I haven't seen. But the strategic point survives it. If you can't beat pembro plus chemo where the comparator is weakest, the commercially interesting version of this molecule is gone regardless of what the biology says.

Then the honest read is that this wasn't a science failure. It was a positioning failure. They aimed at the biggest indication instead of the most winnable one — and the three trials still standing are precisely the ones where the comparator is beatable.

That's the tell. And it lands in a rough stretch. July brought a Wainua miss with Ionis — eplontersen showed no statistically significant cardiovascular benefit in transthyretin amyloid cardiomyopathy. Same month, Ultomiris missed event-free survival in transplant-associated thrombotic microangiopathy. At second-quarter earnings, sonesitatug vedotin missed progression-free survival in the overall gastric population, though it did show an overall survival benefit.

That's a pattern now, not variance.

Even the good news gets a shrug. Their oral GLP-1, elecoglipron, delivered eleven and a half percent placebo-adjusted weight reduction at thirty-six weeks — analysts called the profile encouraging and then pointed out that rival candidates have done better.

Which tells you something about the bar in obesity right now, but that's a different episode.

Here's the competitive read. If you sit anywhere near first-line lung, nothing changed this week — and that IS the change. Pembrolizumab plus chemo still owns PD-L1-low, and the challenger everyone had penciled into the back half of the decade came off the board without a data point. Move your 2029 share assumptions.

And the unresolved question is whether we ever see the numbers. If eVOLVE-Lung02 never gets presented, the next sponsor pointing a dual checkpoint at first-line lung has to run the experiment again to learn what AstraZeneca already knows. A failure you don't publish is a failure the field pays for twice.

Set that next to the other big move of the week and something clicks. Capital went toward assets where the uncertainty has already been spent. LEO Pharma acquired worldwide rights to dersimelagon from Tanabe Pharma — up to four hundred and thirty-five million dollars in upfront and near-term milestones, plus downstream milestones and tiered royalties. Oral, once-daily MC1R agonist, for erythropoietic protoporphyria and X-linked protoporphyria. Phase 3 done. NDA submitted to the FDA in June.

The mechanism is the elegant part, and it's the one place I'll spend a sentence. It drives melanin production, so less light penetrates the skin. You're not blocking a pathway — you're building shade.

I hadn't thought of it that way.

And the endpoint from INSPIRE is the one to notice. Prolongation of average daily sunlight exposure time to first prodromal symptom. That's a functional outcome, not a biochemical surrogate. LEO says the trial hit statistically significant and clinically meaningful results across primary and secondary endpoints — and a payer can price time outdoors. They cannot price a lab value.

LEO takes global development, regulatory and commercial responsibility. This follows the Replay gene therapy acquisition and the 2025 Boehringer partnership on Spevigo. They're assembling a rare dermatology franchise deliberately, one dossier at a time.

It isn't approved, though, and their own release is careful about it — if approved, it would be the first oral therapy for these conditions, and the agency hasn't ruled. So they paid a filed-asset price for filed-asset risk. Fair trade. And it's the contrast that defines the week.

Go on.

One company spent years and a Phase 3 in the largest population in oncology and came away with nothing it can even publish. The other bought a finished dossier for a population you could seat in a stadium. Both are capital allocation. Only one has a knowable answer date.

Which cuts against my instinct, and I'll say so — I usually pay for the engine over the single asset. Optionality is underpriced more often than not. But look at where the premium actually sat this week: filed, orphan, oral, someone else's Phase 3 risk already retired. If you're building a business development list into next year, that's the profile clearing internal committees right now — and it's not the platform story.

The counter is that you can only run that playbook while finished dossiers are available at four hundred and thirty-five million. Everyone chasing de-risked assets is the fastest way to make de-risked assets expensive.

Under the radar this week — a study published August twentieth on people buying gray-market versions of Lilly's retatrutide, the triple GLP-1, GIP and glucagon agonist. They are not getting what trial participants got, and it isn't close. In the trial program, forty-five percent of participants at the highest dose lost thirty percent or more of body weight. The gray-market cohort isn't in that neighborhood.

For a drug with no approval anywhere.

That's what makes it strange. There's a functioning consumer market for a molecule with no label, no dosing guidance, no supply chain. Whatever's in those vials, the pharmacology being tested out there isn't the pharmacology Lilly ran.

And the commercial exposure is real. Retatrutide's efficacy ceiling is the entire investment case — the reporting has it as the most effective obesity agent to reach late-stage trials. If the public's first experience of that name is disappointment, the brand is defined before the launch is. You cannot run a pre-launch narrative against a shadow market you don't control.

The clinical version is worse. Every one of those users becomes a data point somebody eventually cites — prescribers first, payers second, regulators after that. An unapproved drug is accumulating a real-world evidence file it did not generate and cannot correct. That should keep Lilly up at night considerably more than the counterfeit supply does.

Looking at the week ahead, three threads carry forward and not one of them has a date on it — which is itself the story. Volrustomig's remaining programs in mesothelioma, cervical, and head and neck are now the entire investment case for that molecule. The live watch item is whether AstraZeneca ever commits to presenting the lung data.

What I'll be watching is the label — specifically whether it carries both erythropoietic protoporphyria and the X-linked form. In a population this small, indication breadth isn't a detail. It's the whole commercial model.

And on the gray-market study — nothing scheduled, nothing forced. But a published efficacy gap is a fundamentally different argument than a safety anecdote, and that's the door this opens. If you're tracking compounded obesity supply, keep that file open.

That's the week. The one I'll be sitting with is the eVOLVE-Lung02 data we didn't get — I keep picturing the next sponsor designing that same trial without knowing what AstraZeneca already knows. Have a good week, everyone.

And that wraps our Week in Review for Sunday, August 23rd — volrustomig off the board in first-line lung, LEO Pharma buying a finished dossier in porphyria, and a gray market writing retatrutide's reputation before Lilly gets a turn. Follow the show on Spotify, Apple Podcasts, or wherever you listen — you'll start every weekday with this.